Compare Stocks: SPRY, CMPS, OCUL, and ETON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$10.75 -7.5%	$13.30	$4.88 ▼ $15.87	$1.49B	2.55	2.72 million shs	4.97 million shs
ETON Eton Pharmaceuticals	$50.31 -2.0%	$56.49	$14.27 ▼ $66.37	$1.44B	0.9	642,820 shs	469,023 shs
OCUL Ocular Therapeutix	$6.87 -6.9%	$9.56	$6.23 ▼ $16.44	$1.51B	1	3.96 million shs	2.76 million shs
SPRY ARS Pharmaceuticals	$4.02 -1.2%	$4.98	$3.81 ▼ $13.15	$399.78M	0.85	1.44 million shs	2.33 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	0.00%	-10.42%	-28.33%	-12.96%	+57.39%
ETON Eton Pharmaceuticals	0.00%	-8.88%	-11.85%	+18.88%	+162.72%
OCUL Ocular Therapeutix	0.00%	-8.89%	-32.25%	-23.41%	-42.46%
SPRY ARS Pharmaceuticals	0.00%	-4.96%	-3.13%	-42.57%	-63.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$10.75 -7.5%	$13.30	$4.88 ▼ $15.87	$1.49B	2.55	2.72 million shs	4.97 million shs
ETON Eton Pharmaceuticals	$50.31 -2.0%	$56.49	$14.27 ▼ $66.37	$1.44B	0.9	642,820 shs	469,023 shs
OCUL Ocular Therapeutix	$6.87 -6.9%	$9.56	$6.23 ▼ $16.44	$1.51B	1	3.96 million shs	2.76 million shs
SPRY ARS Pharmaceuticals	$4.02 -1.2%	$4.98	$3.81 ▼ $13.15	$399.78M	0.85	1.44 million shs	2.33 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	0.00%	-10.42%	-28.33%	-12.96%	+57.39%
ETON Eton Pharmaceuticals	0.00%	-8.88%	-11.85%	+18.88%	+162.72%
OCUL Ocular Therapeutix	0.00%	-8.89%	-32.25%	-23.41%	-42.46%
SPRY ARS Pharmaceuticals	0.00%	-4.96%	-3.13%	-42.57%	-63.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	117.28% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$71.50	42.12% Upside
OCUL Ocular Therapeutix	2.83	Moderate Buy	$22.86	232.71% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	521.89% Upside

Current Analyst Ratings Breakdown

Latest SPRY, CMPS, OCUL, and ETON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	CMPS Compass Pathways	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	OCUL Ocular Therapeutix	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$78.00
10/14/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$70.00
10/12/2026	ETON Eton Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/11/2026	OCUL Ocular Therapeutix	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$14.00
10/11/2026	OCUL Ocular Therapeutix	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/2/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$23.00
9/29/2026	OCUL Ocular Therapeutix	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/29/2026	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$18.00
9/22/2026	ETON Eton Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Hold (C)

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS Compass Pathways	N/A	N/A	N/A	N/A	($0.55) per share	N/A
ETON Eton Pharmaceuticals	$105.60M	13.62	$0.01 per share	9,706.36	$0.98 per share	51.34
OCUL Ocular Therapeutix	$52.06M	28.98	N/A	N/A	$3.07 per share	2.24
SPRY ARS Pharmaceuticals	$84.28M	4.74	N/A	N/A	$1.16 per share	3.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-49.63%	-13.08%	11/3/2026 (Estimated)
ETON Eton Pharmaceuticals	-$4.60M	$0.38	132.39	25.93	N/A	12.02%	40.13%	12.37%	11/5/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest SPRY, CMPS, OCUL, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	SPRY ARS Pharmaceuticals	-$0.34	N/A	N/A	N/A	$41.99 million	N/A
11/5/2026	Q3 2026	ETON Eton Pharmaceuticals	$0.3125	N/A	N/A	N/A	$41.99 million	N/A
11/3/2026	Q3 2026	CMPS Compass Pathways	-$0.3629	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	OCUL Ocular Therapeutix	-$0.3648	N/A	N/A	N/A	$14.27 million	N/A
8/13/2026	Q2 2026	ETON Eton Pharmaceuticals	$0.1898	$0.43	+$0.2402	$0.35	$27.11 million	$37.59 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS Compass Pathways	0.60	1.30	1.30
ETON Eton Pharmaceuticals	0.41	1.52	1.30
OCUL Ocular Therapeutix	0.14	13.10	13.03
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS Compass Pathways	46.19%
ETON Eton Pharmaceuticals	27.86%
OCUL Ocular Therapeutix	59.21%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
CMPS Compass Pathways	2.82%
ETON Eton Pharmaceuticals	16.49%
OCUL Ocular Therapeutix	3.10%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS Compass Pathways	156	138.48 million	134.57 million	Optionable
ETON Eton Pharmaceuticals	44	28.58 million	23.87 million	Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable

SPRY, CMPS, OCUL, and ETON Headlines

Recent News About These Companies

Head to Head Analysis: ARS Pharmaceuticals (NASDAQ:SPRY) vs. Vanda Pharmaceuticals (NASDAQ:VNDA)

October 8, 2026 | americanbankingnews.com

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 5, 2026 | tmcnet.com

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

October 5, 2026 | prnewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 5, 2026 | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

October 4, 2026 | newsfilecorp.comN

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 4, 2026 | newsfilecorp.comN

SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 3, 2026 | newsfilecorp.comN

ARS PHARMACEUTICALS DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

October 3, 2026 | newsfilecorp.comN

ARS Pharmaceuticals Officer Eric Karas Files Form 144 to Sell 100,000 Shares on NASDAQ

October 2, 2026 | kalkinemedia.comK

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

October 2, 2026 | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

October 2, 2026 | globenewswire.com

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

October 2, 2026 | globenewswire.com

Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026

October 1, 2026 | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 1, 2026 | globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 1, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

October 1, 2026 | prnewswire.com

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 1, 2026 | prnewswire.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00

October 1, 2026 | marketbeat.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

September 30, 2026 | newsfilecorp.comN

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

September 30, 2026 | prnewswire.com

ARS Pharmaceuticals, Inc. (SPRY)

September 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, CMPS, OCUL, and ETON Company Descriptions

Compass Pathways NASDAQ:CMPS

$10.75 -0.87 (-7.49%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$10.91 +0.16 (+1.49%)

As of 10/16/2026 07:55 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Eton Pharmaceuticals NASDAQ:ETON

$50.31 -1.02 (-1.99%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$51.79 +1.48 (+2.94%)

As of 10/16/2026 07:30 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Ocular Therapeutix NASDAQ:OCUL

$6.87 -0.51 (-6.91%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$6.97 +0.10 (+1.47%)

As of 10/16/2026 07:30 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$4.02 -0.05 (-1.23%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$4.01 0.00 (-0.12%)

As of 10/16/2026 07:30 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRY, CMPS, OCUL, and ETON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRY, CMPS, OCUL, and ETON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRY, CMPS, OCUL, and ETON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, CMPS, OCUL, and ETON Company Descriptions

Compass Pathways NASDAQ:CMPS

Eton Pharmaceuticals NASDAQ:ETON

Ocular Therapeutix NASDAQ:OCUL

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRY, CMPS, OCUL, and ETON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRY, CMPS, OCUL, and ETON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRY, CMPS, OCUL, and ETON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, CMPS, OCUL, and ETON Company Descriptions

Compass Pathways NASDAQ:CMPS

Eton Pharmaceuticals NASDAQ:ETON

Ocular Therapeutix NASDAQ:OCUL

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools